Pharmacokinetic interference of doxorubicin with tolbutamide due to reduced metabolic clearance with increased serum unbound fraction in rats
- 18 June 2019
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 40 (7) , 225-233
Abstract
We examined the effect of doxorubicin (DOX) on hepatic expression of CYP2C and its activity for metabolizing tolbutamide (TB), a specific CYP2C substrate, in rats and whether the pharmacokinetics of TB were altered by DOX exposure. The expression level of hepatic CYP2C11 was depressed 1 day after DOX administration (Day 1), and this effect on CYP2C11 was augmented on Day 4. However, the expression level of hepatic CYP2C6 remained unchanged. Activity of TB 4‐hydroxylation in hepatic microsomes was decreased with time following DOX administration. Regarding the enzyme kinetic parameters for TB 4‐hydroxylation on Day 4, the maximum velocity (Vmax) was significantly lower in the DOX group than that in the control group, while the Michaelis constant (Km) was unaffected. On pharmacokinetic examination, the total clearance (CLtot) of TB on Day 4 was increased despite the decreased metabolic capacity. On the other hand, the serum unbound fraction (fu) of TB was elevated with a reduced serum albumin concentration in the DOX group. Contrary to CLtot, CLtot/fu, a parameter approximated to hepatic intrinsic clearance of unbound TB, was estimated to be significantly reduced in the DOX group. These findings indicate that the metabolic capacity of CYP2C11 in the liver is depressed time‐dependently by down‐regulation after DOX exposure in rats, and that the decreased enzyme activity of TB 4‐hydroxylation in hepatic microsomes reflects the pharmacokinetic change of unbound TB, not total TB, in serum.Keywords
This publication has 28 references indexed in Scilit:
- Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human LiverDrug Metabolism and Disposition, 2008
- Effect of methamphetamine on cytochrome P450 activityXenobiotica, 2007
- Relationship between structural features and in vitro release of doxorubicin from biocompatible anionic microemulsionColloids and Surfaces B: Biointerfaces, 2007
- Differential alteration of drug metabolizing enzyme activities after cyclohosphamide/adriamycin administation in breast cancer patientsMethods and Findings in Experimental and Clinical Pharmacology, 2007
- Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatmentEuropean Neuropsychopharmacology, 2006
- Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and manXenobiotica, 2000
- Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicinCanadian Journal of Physiology and Pharmacology, 1999
- Protein binding and hepatic clearance: Studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver preparationJournal of Pharmacokinetics and Biopharmaceutics, 1983
- Clinical Pharmacokinetics of PhenytoinClinical Pharmacokinetics, 1979
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976